- Home
- FCT vs NMRA Comparison
FCT vs NMRA Comparison
Compare FCT & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCT
- NMRA
- Stock Information
- Founded
- FCT 2004
- NMRA 2019
- Country
- FCT United States
- NMRA United States
- Employees
- FCT N/A
- NMRA N/A
- Industry
- FCT Finance Companies
- NMRA
- Sector
- FCT Finance
- NMRA
- Exchange
- FCT Nasdaq
- NMRA Nasdaq
- Market Cap
- FCT 261.0M
- NMRA 268.5M
- IPO Year
- FCT N/A
- NMRA 2023
- Fundamental
- Price
- FCT $10.07
- NMRA $1.63
- Analyst Decision
- FCT
- NMRA Buy
- Analyst Count
- FCT 0
- NMRA 8
- Target Price
- FCT N/A
- NMRA $7.14
- AVG Volume (30 Days)
- FCT 106.8K
- NMRA 1.4M
- Earning Date
- FCT 01-01-0001
- NMRA 08-06-2025
- Dividend Yield
- FCT 11.29%
- NMRA N/A
- EPS Growth
- FCT N/A
- NMRA N/A
- EPS
- FCT N/A
- NMRA N/A
- Revenue
- FCT N/A
- NMRA N/A
- Revenue This Year
- FCT N/A
- NMRA N/A
- Revenue Next Year
- FCT N/A
- NMRA N/A
- P/E Ratio
- FCT N/A
- NMRA N/A
- Revenue Growth
- FCT N/A
- NMRA N/A
- 52 Week Low
- FCT $9.45
- NMRA $0.61
- 52 Week High
- FCT $10.42
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- FCT 47.00
- NMRA 52.38
- Support Level
- FCT $9.99
- NMRA $1.49
- Resistance Level
- FCT $10.09
- NMRA $1.70
- Average True Range (ATR)
- FCT 0.08
- NMRA 0.18
- MACD
- FCT -0.02
- NMRA -0.06
- Stochastic Oscillator
- FCT 27.42
- NMRA 25.00
About FCT First Trust Senior Floating Rate Income Fund II of Beneficial Interest
First Trust Senior Floating Rate Income Fund II is a United States-based diversified, closed-end management investment company. Its investment objective is to seek a high level of current income. As a secondary objective, it attempts to preserve capital. The fund invests in a portfolio of senior secured floating-rate corporate loans (Senior Loans) of companies from different industries, such as Insurance, Software, Health Care Providers and Services, Professional Services, Health Care Technology, IT Services, and others.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.